Dendrimer-based compositions and methods are provided, that are useful for administering pharmaceutical compositions to target cells and tissues for treatment of ocular diseases including macular degeneration, diabetic retinopathy, and retinitis pigmentosa.

The invention generally relates to the fields of drug delivery and cell capture. In particular, the invention relates to amphiphilic dendron-coils, micelles thereof and their use for drug delivery vehicles and/or cell capture.

Brominated vinylaromatic-diene block copolymers (Br-SBC) comprising a vinylaromatic polymer block S and a brominated diene polymer block BB, wherein before bromination the weight-average molar mass M.sub.w of the block S is greater than or equal to M.sub.w of the block BB, use thereof as flame retardants, and also polymer compositions comprising these for unfoamed and foamed thermoplastic polymers, for example EPS and XPS.

The present invention relates to a compound having a macromolecular carrier having a plurality of terminal groups, wherein the carbonyl group of serine is linked by a peptide bond or an ester bond directly or via a linker to the terminal groups, a carrier for drug delivery composed of the compound, and a medicament for preventing or treating renal diseases, containing the carrier for drug delivery and a drug bonded to the carrier directly or via a linker or encapsulated therein. According to the present invention, a carrier for drug delivery that is selectively accumulated in kidney in vivo can be provided.

Provided herein are dendrimers comprising: a core unit, five generations of building units which are lysine residues or analogues thereof, first terminal groups comprising a cabazitazel residue covalently attached to a diglycolyl linker group, and second terminal groups comprising a PEG group. Also provided herein are pharmaceutical compositions comprising the dendrimers, and methods and uses of the dendrimers in therapy of disorders such as cancers. Processes for making the dendrimers and intermediates are also provided.

A catalytic cracking process includes a step of contacting a cracking feedstock with a catalytic cracking catalyst in the presence of a radical initiator for reaction under catalytic cracking conditions. The radical initiator contains a dendritic polymer and/or a hyperbranched polymer. The dendritic polymer and the hyperbranched polymer each independently has a degree of branching of about 0.3-1, and each independently has a weight average molecular weight of greater than about 1000. The catalytic cracking process is beneficial to enhancing and accelerating the free radical cracking of petroleum hydrocarbon and promoting the regulation of cracking activity and product distribution; by using the process disclosed herein, the conversion of catalytic cracking can be improved, the yields of ethylene and propylene can be increased, and the yield of coke can be reduced.

Provided herein are dendrimers comprising: a core unit, five generations of building units which are lysine residues or analogues thereof, first terminal groups comprising a cabazitazel residue covalently attached to a diglycolyl linker group, and second terminal groups comprising a PEG group. Also provided herein are pharmaceutical compositions comprising the dendrimers, and methods and uses of the dendrimers in therapy of disorders such as cancers. Processes for making the dendrimers and intermediates are also provided.

Methods for processing polynucleotide-containing biological samples, and materials for capturing polynucleotide molecules such as RNA and/or DNA from such samples. The RNA and/or DNA is captured by polyamindoamine (PAMAM (Generation 0)) bound to a surface, such as the surface of magnetic particles. The methods and materials have high efficiency of binding RNA and of DNA, and of release, and thereby permit quantitative determinations.

Disclosed are hydrogels polymerized with a biofunctional moiety, biodegradable and permanent, designed to be implantable in a mammalian body and intended to block or mitigate the formation of tissue adhesions. The hydrogels of the present invention are characterized by comprising four structural elements: a) a polymeric backbone which defines the overall polymeric morphology, b) linkage groups, c) side chains, and d) biofunctional end groups. The hydrophobicity of the various structural elements are chosen to reduce tissue adhesion and enhance the biofunctional aspect of the end groups. The morphology of these polymers are typically of high molecular weight and have shape to encourage entanglement. Useful structures include branching chains, comb or brush, and dendritic morphologies.

A synthesis method includes synthesising copolydendrimers containing heteroatoms from at least two dendrimers as starting precursors.